Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Approaches to Testing Novel β-Lactam and β-Lactam Combination Agents in the Clinical Laboratory

5 Dec 2023

Abstract excerpt

The rapid emergence of multi-drug resistant Gram-negative pathogens has driven the introduction of novel β-lactam combination agents (BLCs) to the antibiotic market: ceftolozane-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, cefiderocol, and sulbactam-durlobactam. These agents are equipped with innovative mechanisms that confer broad Gram-negative activity, notably against certain...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotic Resistance in Bacteria
Share to Antibiotic Use and Resistance
Share to Antibiotics Pharmacokinetics and Efficacy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38136734
DOI: 10.3390/antibiotics12121700

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Approaches to Testing Novel β-Lactam and β-Lactam Combination Agents in the Clinical LaboratoryPMID 38136734Read ↗

Beta-lactams and Beta-lactamase-inhibitors in current- or potential-clinical practice: A comprehensive updateSemantic proximity Read ↗

β-Lactam Antibiotics and β-Lactamase Enzymes Inhibitors, Part 2: Our Limited ResourcesSemantic proximity Read ↗

Epidemiology and Mechanisms of Ceftazidime–Avibactam Resistance in Gram-Negative BacteriaSemantic proximity Read ↗

Extended-spectrum β-lactamases: an update on their characteristics, epidemiology and detectionSemantic proximity Read ↗

New Carbapenemase Inhibitors: Clearing the Way for the β-LactamsSemantic proximity Read ↗

Advancements in the fight against globally distributed OXA-48 carbapenemase: evaluating the new generation of carbapenemase inhibitorsSemantic proximity Read ↗

Recent advances in rapid antimicrobial susceptibility testing systemsSemantic proximity Read ↗

beta-Lactamases in laboratory and clinical resistanceSemantic proximity Read ↗

The Growing Genetic and Functional Diversity of Extended Spectrum Beta-LactamasesSemantic proximity Read ↗

Carbapenemase-Producing Gram-Negative Bacteria: Current Epidemics, Antimicrobial Susceptibility and Treatment OptionsSemantic proximity Read ↗

Update of clinical application in ceftazidime–avibactam for multidrug-resistant Gram-negative bacteria infectionsSemantic proximity Read ↗

Durlobactam, a New Diazabicyclooctane β-Lactamase Inhibitor for the Treatment of Acinetobacter Infections in Combination With SulbactamSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.